MedTrace Logo

Biomarkers and Outcome 1 and 10-15 Years After Severe Traumatic Brain Injury

NCT05138692 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99

Last updated 2021-12-01

No results posted yet for this study

Summary

After written consent from next-of-kin patients with severe traumatic brain injury was included from the neurointensive care unit (NICU) at Sahlgrenska university hospital, Gothenburg. Blood and CSF samples were collected during the initial 3 weeks after trauma. 1 year after trauma patients were assessed according to Glasgow outcome scale (GOS), NIHSS and Barthels. 10-15 years after trauma a repeated evaluation according to GOS was performed by telephone. Different biomarkers such as Neurofilament light, Glial fibrillary acidic protein and Tau among others, was analyzed from serum and CSF samples. Further patients were explored Apolipoprotein-E genetype (APOE). The investigators hypothesize that higher biomarkers concentrations and positive test for this gene relate to worse outcome 1-year and 10-15 years after trauma. Further that these biomarkers and genetic marker further have prognostic value on outcome 1-year and 10-15 years after trauma. Finally, the investigators want to explore the concentrations dynamics of these biomarkers in serum and CSF in the acute phase after trauma.

Conditions

  • Brain Injury Traumatic Severe (Diagnosis)
  • Biomarkers

Sponsors & Collaborators

  • Svenska alzheimerfonden

    collaborator UNKNOWN

  • Stroke Foundation

    collaborator UNKNOWN

  • Bengt Nellgard

    lead OTHER

Principal Investigators

  • Bengt Nellgård, MD PhD Professor · University of Gothenburg and Västra götaland Regionen, Sahlgrenska Universitetssjukhus Mölndal

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-01
Primary Completion
2016-12-01
Completion
2016-12-01

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05138692 on ClinicalTrials.gov